Perrin E Romine1, Jenna Voutsinas2, Vicky Wu2, Micah Tratt3, Jay Liao4, Upendra Parvathaneni4, Brittany Barber5, Jasjit Dillon6, Mari-Alina Timoshchuk7, Neal Futran5, Jeffrey Houlton5, George Laramore4, Renato Martins3, Keith D Eaton3, Cristina Rodriguez3. 1. University of Washington, Department of Medicine, Division of Medical Oncology, United States. Electronic address: perrinr@uw.edu. 2. Fred Hutchinson Cancer Research Institute, Division of Clinical Biostatistics, United States. 3. University of Washington, Department of Medicine, Division of Medical Oncology, United States. 4. University of Washington, Department of Radiation Oncology, United States. 5. University of Washington, Department of Otolaryngology, United States. 6. University of Washington, Department of Oral and Maxillofacial Surgery, United States. 7. Louisiana State University, Department of Oral and Maxillofacial Surgery, New Orleans, LA, United States.
Abstract
OBJECTIVES: Timely administration of postoperative radiation therapy (PORT) impacts oncologic outcomes in resected squamous cell carcinomas of the head and neck. Salivary gland cancers (SGCs) are uncommon, and timing of PORT has not been extensively explored. We aimed to determine if the interval between surgery and PORT impacts outcomes in SGCs. MATERIALS AND METHODS: This is a retrospective study of patients with SGCs who underwent curative intent surgical resection followed by adjuvant PORT. Locoregional recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS) were estimated using the Kaplan Meier method. A multivariate analysis explored the association between demographics, tumor characteristics, and PORT timing with oncologic outcomes using a stepwise Cox proportional hazards model. RESULTS: 180 eligible patients were identified. The median time to PORT start was 61 (range 8-121) days. 169 (93.5%) of patients received neutron radiation. With a median follow up of 8.2 years in surviving patients, the 10-year OS and LRFS estimates were 61% and 53%. In a multivariate analysis, nodal involvement, histologic grade, and age at diagnosis were associated with OS, while nodal involvement, tumor size, and age at diagnosis were associated with LRFS and DFS. Time to PORT start or completion was not statistically associated with survival outcomes. CONCLUSION: SGC patients who underwent surgery in our tertiary institution received PORT within a median of 61 days after surgery. With long term follow up, PORT timing in this retrospective series was not associated with worse oncologic outcomes, and support timely administration of PORT.
OBJECTIVES: Timely administration of postoperative radiation therapy (PORT) impacts oncologic outcomes in resected squamous cell carcinomas of the head and neck. Salivary gland cancers (SGCs) are uncommon, and timing of PORT has not been extensively explored. We aimed to determine if the interval between surgery and PORT impacts outcomes in SGCs. MATERIALS AND METHODS: This is a retrospective study of patients with SGCs who underwent curative intent surgical resection followed by adjuvant PORT. Locoregional recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS) were estimated using the Kaplan Meier method. A multivariate analysis explored the association between demographics, tumor characteristics, and PORT timing with oncologic outcomes using a stepwise Cox proportional hazards model. RESULTS: 180 eligible patients were identified. The median time to PORT start was 61 (range 8-121) days. 169 (93.5%) of patients received neutron radiation. With a median follow up of 8.2 years in surviving patients, the 10-year OS and LRFS estimates were 61% and 53%. In a multivariate analysis, nodal involvement, histologic grade, and age at diagnosis were associated with OS, while nodal involvement, tumor size, and age at diagnosis were associated with LRFS and DFS. Time to PORT start or completion was not statistically associated with survival outcomes. CONCLUSION: SGC patients who underwent surgery in our tertiary institution received PORT within a median of 61 days after surgery. With long term follow up, PORT timing in this retrospective series was not associated with worse oncologic outcomes, and support timely administration of PORT.
Authors: Evan M Graboyes; Elizabeth Garrett-Mayer; Mark A Ellis; Anand K Sharma; Amy E Wahlquist; Eric J Lentsch; Brian Nussenbaum; Terry A Day Journal: Cancer Date: 2017-08-25 Impact factor: 6.860
Authors: Ali Hosni; Shao Hui Huang; David Goldstein; Wei Xu; Biu Chan; Aaron Hansen; Ilan Weinreb; Scott V Bratman; John Cho; Meredith Giuliani; Andrew Hope; John Kim; Brian O'Sullivan; John Waldron; Jolie Ringash Journal: Oral Oncol Date: 2015-12-23 Impact factor: 5.337
Authors: G E Laramore; J M Krall; T W Griffin; W Duncan; M P Richter; K R Saroja; M H Maor; L W Davis Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: Allen S Ho; Sungjin Kim; Mourad Tighiouart; Alain Mita; Kevin S Scher; Joel B Epstein; Anna Laury; Ravi Prasad; Nabilah Ali; Chrysanta Patio; Jon Mallen-St Clair; Zachary S Zumsteg Journal: Cancer Date: 2018-05-09 Impact factor: 6.860